A detailed history of Jpmorgan Chase & CO transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,199,975 shares of SAGE stock, worth $8.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,199,975
Previous 1,154,716 3.92%
Holding current value
$8.65 Million
Previous $21.6 Million 39.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$10.58 - $17.9 $478,840 - $810,136
45,259 Added 3.92%
1,199,975 $13 Million
Q1 2024

May 10, 2024

SELL
$18.62 - $26.95 $9.61 Million - $13.9 Million
-515,999 Reduced 30.88%
1,154,716 $21.6 Million
Q4 2023

Feb 12, 2024

BUY
$17.1 - $22.26 $37,568 - $48,905
2,197 Added 0.13%
1,670,715 $36.2 Million
Q3 2023

Nov 14, 2023

SELL
$16.75 - $48.98 $403,273 - $1.18 Million
-24,076 Reduced 1.42%
1,668,518 $34.3 Million
Q2 2023

Aug 11, 2023

BUY
$40.65 - $59.54 $12.9 Million - $18.9 Million
317,276 Added 23.07%
1,692,594 $79.6 Million
Q1 2023

May 18, 2023

BUY
$37.27 - $46.57 $2.43 Million - $3.04 Million
65,256 Added 4.98%
1,375,318 $57.7 Million
Q1 2023

May 11, 2023

SELL
$37.27 - $46.57 $3.83 Million - $4.79 Million
-102,769 Reduced 7.27%
1,310,062 $55 Million
Q4 2022

Feb 13, 2023

SELL
$32.2 - $43.61 $3.73 Million - $5.06 Million
-115,916 Reduced 7.58%
1,412,831 $53.9 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $733,401 - $983,094
-22,720 Reduced 1.46%
1,528,747 $59.9 Million
Q2 2022

Aug 11, 2022

SELL
$27.52 - $37.99 $1.71 Million - $2.36 Million
-62,183 Reduced 3.85%
1,551,467 $50.1 Million
Q1 2022

May 11, 2022

BUY
$30.71 - $45.71 $1.6 Million - $2.38 Million
52,028 Added 3.33%
1,613,650 $53.4 Million
Q4 2021

Feb 10, 2022

BUY
$37.06 - $47.11 $14.7 Million - $18.7 Million
397,001 Added 34.09%
1,561,622 $66.4 Million
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $46.9 Million - $66.8 Million
1,164,621 New
1,164,621 $51.6 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $428M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.